Mupirocin
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Mupirocin: Pleural empyema (disease)
One-Sentence Summary
Mupirocin is a topical antibacterial originally used to treat impetigo and bullous impetigo. The top-ranked TxGNN prediction, pleural empyema, has no supporting evidence at all, so this report focuses on SSSS as the most credible candidate.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Pleural empyema (disease) |
| TxGNN Prediction Score | 0.9949 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. From general pharmacology, mupirocin is a topical antibiotic that inhibits bacterial isoleucyl-tRNA synthetase, which blocks bacterial protein synthesis. It is mainly active against Gram-positive bacteria, especially Staphylococcus aureus.
SSSS is caused by S. aureus strains that produce exfoliative toxins. Bullous impetigo, one of mupirocin’s original indications, is the localized form of the same toxin-mediated spectrum. SSSS is the severe, widespread end of that spectrum. Because mupirocin already targets the causative organism in the localized disease, it is reasonable to consider it for skin care in SSSS.
Mupirocin would be an add-on, not a replacement for systemic antibiotics, which remain the core therapy. A 2023 retrospective study (PMID 37404367) examined intravenous antibiotics combined with 2% mupirocin ointment in children with SSSS. Resistance is a concern. Two Greek reports describe a mupirocin- and fusidic acid-resistant S. aureus clone (ST121) carrying exfoliative toxin genes.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The 12 publications listed below are the most relevant of those compiled for SSSS. Evidence was ranked by study type, but no RCTs were found.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37404367 | 2023 | Retrospective cohort | Clin Cosmet Investig Dermatol | Compared treatment duration, influencing factors and costs among intravenous antibiotic groups combined with 2% mupirocin ointment in paediatric SSSS |
| 15482208 | 2004 | Review | Expert Rev Anti Infect Ther | Treatment of bullous impetigo and SSSS in infants; both are caused by staphylococcal exfoliative toxin |
| 35901469 | 2022 | Case series | Adv Neonatal Care | SSSS identification and wound care in neonates, a group at higher risk of MSSA infection |
| 42509990 | 2026 | Retrospective cohort | Children (Basel) | 11-year review of paediatric SSSS: epidemiology, microbiology, management and complications |
| 8435912 | 1993 | Review | Dermatol Clin | Staphylococcal control in skin disease; topical mupirocin described as a valuable addition for impetigo and furunculosis |
| 30418106 | 2019 | Epidemiology/molecular | J Med Microbiol | New toxin-producing MSSA clone (ST121) resistant to mupirocin and fusidic acid, linked to rising SSSS cases |
| 28592549 | 2017 | Retrospective review | J Clin Microbiol | Emergence of a mupirocin- and fusidic acid-resistant S. aureus clone carrying exotoxin genes, mainly causing skin infections |
| 31725120 | 2020 | Epidemiology/cohort | Pediatr Infect Dis J | Increasing SSSS cases caused by ST121 at a Houston children’s hospital |
| 16009455 | 2005 | Outbreak investigation | J Hosp Infect | Nosocomial SSSS outbreak in 13 neonates; epidemiological investigation and control |
| 9576389 | 1998 | Molecular epidemiology | Pediatr Infect Dis J | Two SSSS cases in very low birth weight infants; infection control prevented an outbreak |
| 35358031 | 2022 | Epidemiology/cohort | J Med Microbiol | Community-associated MSSA predominates among hospitalized children and adolescents |
| 27047925 | 2014 | Case report | Dermatopathology (Basel) | SSSS in an adult receiving chemotherapy for leukaemia |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02279983 | TARO-MUPIROCIN | Not specified | Not specified |
| 02483459 | STRAMUCIN | Not specified | Not specified |
Safety Considerations
- Contraindications (knowledge graph, not label text): The TxGNN knowledge graph lists a drug-disease contraindication link with dermatitis. This should be checked against the package insert.
- Drug Interactions: The interaction database returned 100 records. The 20 reviewed here (including calcitriol, clotrimazole, morphine, metformin, pantoprazole, omeprazole, vancomycin and prednisone) all have an unclassified severity level, so no clinical significance can be assigned from the data compiled.
- Ocular use: An in vitro study (PMID 8222720) reported corneal epithelial toxicity for several antimicrobials including mupirocin, which is a concern for any eye-related use.
- Neonates: In neonates with SSSS, the compromised skin barrier raises the risk of systemic absorption, so the area treated should be limited.
Please refer to the Health Canada package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale:
- For SSSS, mupirocin has a plausible mechanism, shares the pathophysiology of its approved bullous impetigo indication, and has supporting retrospective and observational literature, including a study of mupirocin combined with intravenous antibiotics. There are no RCTs or registered trials, so it should be used only as a topical adjunct to systemic antibiotics.
- The other nine predictions are not recommended for advancement. Pleural empyema, punctate epithelial keratoconjunctivitis, neurotrophic keratopathy, vaginal discharge, leukoplakia of vagina and non-human animal disease have only model predictions and no supporting studies (Hold).
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications, which are currently missing and block formal safety screening
- Approved indication text and dosage form details for both Canadian products
- Mechanism of action data confirmed from DrugBank
- Full-text review of PMID 37404367 to confirm the design, outcomes and the contribution of mupirocin
- Local mupirocin resistance surveillance data, given the reported resistant ST121 clone
- A guardrail protocol for neonates and infants covering application area limits and absorption monitoring
- Ideally a prospective study or registry comparing systemic antibiotics with and without topical mupirocin in SSSS
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.